Your session is about to expire
← Back to Search
Behavioural Intervention
Home-Based Exercise for Prostate Cancer
N/A
Recruiting
Led By Paul Viscuse, MD
Research Sponsored by Paul Viscuse
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Planned treatment with ADT (LHRH agonist such as leuprolide or LHRH antagonist such as degarelix), and intensification with ARSI (abiraterone/prednisone, enzalutamide, apalutamide, or darolutamide)
Male, aged ≥18 years old
Must not have
Metastatic bone lesion(s) in the proximal femur, bone lesion causing impending fracture, or other metastatic site deemed unsafe for walking by treating physician
Uncontrolled metabolic disease (diabetes with fasting blood sugar >300 mg/dl, thyrotoxicosis, myxedema)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured at the baseline visit before the start of the intervention and post-intervention visit (about 16 weeks later
Awards & highlights
Summary
This trial involves two different exercise programs that can be done at home: one using a stationary exercise bike (Arm A) and the other involving walking (Arm B). The study will include 24 patients
Who is the study for?
This trial is for patients with newly diagnosed metastatic castrate-sensitive prostate cancer (mCSPC) who are starting ADT/ARSI therapy. Participants will need to complete training at UVA and be able to do aerobic and strength testing before and after a 12-week home-based exercise program.
What is being tested?
The study tests two types of home-based exercise programs: one involving stationary cycling (HIIT Cycling), the other walking. The goal is to see how these exercises affect patients undergoing ADT/ARSI treatment for mCSPC over a period of 12 weeks.
What are the potential side effects?
Since this trial involves non-drug interventions like walking and cycling, side effects may include typical exercise-related issues such as muscle soreness, fatigue, or injury from physical activity.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am scheduled for hormone therapy with additional advanced prostate cancer medication.
Select...
I am a man aged 18 or older.
Select...
I have prostate cancer that has spread, confirmed by biopsy or high PSA and imaging.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have cancer spread to my bones that affects my ability to walk.
Select...
I do not have uncontrolled diabetes or thyroid issues.
Select...
I cannot cycle or walk due to other health issues.
Select...
I have severe symptoms from a narrowed heart valve.
Select...
I have had a recent blood clot in my lung.
Select...
I have inflammation of the heart muscle.
Select...
I have had a recent bleeding in my eye.
Select...
I have been treated with taxane or platinum chemotherapy before.
Select...
I have a severe form of retinopathy that hasn't been treated.
Select...
My prostate cancer returned after treatment, but scans show no spread.
Select...
I have been treated with PARP inhibitors before.
Select...
My prostate cancer is resistant to hormonal therapy and has worsened despite treatment.
Select...
I do not have major heart, kidney, liver, blood, or lung conditions that prevent me from exercising.
Select...
I have severe heart symptoms or irregular heartbeats.
Select...
I have symptoms from poor blood flow in my limbs.
Select...
I have previously been treated with radium-223 or lutetium-177.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ measured at the baseline visit before the start of the intervention and post-intervention visit (about 16 weeks later)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured at the baseline visit before the start of the intervention and post-intervention visit (about 16 weeks later)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of participants who complete the post-intervention follow-up assessment
Secondary outcome measures
Acceptability of exercise
Muscular strength (quadriceps)
Patient-reported outcomes on exercise
+3 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: Arm BExperimental Treatment1 Intervention
Walking Intervention
Group II: Arm AExperimental Treatment1 Intervention
HIIT Cycling Intervention
Find a Location
Who is running the clinical trial?
Paul ViscuseLead Sponsor
Paul Viscuse, MDPrincipal InvestigatorUniversity of Virginia
Share this study with friends
Copy Link
Messenger